Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
Suominen is a manufacturing company. The company manufactures and develops a wide range of wipes, hygiene products and medical applications. The manufacturing is based on non-woven fabrics that can be used for various purposes. Customers are found in several industries, with the largest operations in Europe and North America. The company has its headquarters in Helsinki.
Suominen's Q3 comparable EBITDA was slightly ahead of Vara Research consensus. The company alluded to continued operational improvements and stronger production volumes in Q3. However, we note persistent production challenges in the US that could continue...
Suomisens omsætning for Q3 voksede med 1,3 % og lå cirka 8 % under vores estimater som følge af produktionsforstyrrelser i USA, men det justerede EBITDA (5,1 MEUR) og driftsresultatet overgik forventningerne. Pengestrømmen fra driften trak markant ned i minus på grund af en stigning i arbejdskapitalen. Administrerende direktør Charles Héaulmé kommenterer i et interview med analytiker Rauli Juva.
Bliv en del af Inderes community
Gå ikke glip af noget - opret en konto og få alle de mulige fordele
Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Suominen Q2 comparable EBITDA of EUR 5.1m came 8% above Vara Research consensus expectations. Net sales of EUR 101m were up 1% y/y and came 7% below consensus. FX had EUR 1.4m posigive impact on sales. EBITDA improvement was mainly related to higher ...
Vi estimerer, at Suomisen fornyer sin virksomhedsobligation i de kommende måneder, og vi har opjusteret vores estimater for finansieringsomkostningerne for de kommende år.
Suominen's Q2 comparable EBITDA was clearly ahead of Vara Research consensus, supported by improving volumes and lower fixed costs. Self-help measures started to support development while the company noted an unfavourable mix and difficulties in meeting...
Suomisens regnskabsmeddelelse for 2. kvartal var bedre end vores forventninger og sammenligningsperioden. Resultatniveauet er dog stadig absolut svagt.
Following its rights issue, Suominen's strengthened balance sheet now allows the company to fully focus on executing its Full Potential turnaround program. However, there is still plenty of work ahead.
Suominen Q2 comparable EBITDA of EUR 4.3m came 45% above Vara Research consensus expectations. Net sales of EUR 106m were up 6% y/y and came 1% below consensus. FX had EUR 1.3m negative impact on sales. EBITDA improvement was mainly related to higher...
